Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 78 of 6351
-
New trial aims to spare young brains from radiation damage
Disease control Recruiting nowChildren diagnosed with benign or low-grade brain tumors often require radiation therapy to control their disease. While radiation can be effective, traditional techniques using X-rays (photon-based radiotherapy) expose healthy brain tissue to radiation, potentially leading to lo…
Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on stomach cancer in Late-Stage trial
Disease control Recruiting nowAn open-label, randomized, comparative phase II study including patients with CLDN18.2-positive unresectable locally advanced gastric cancer. To evaluate the objective response rate (ORR) and progression-free survival (PFS) of IMC002 compared with investigator's choice of treatme…
Phase 3 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Wearable patch could warn of deadly Post-Birth bleeding an hour before it happens
Diagnosis OngoingOli is a predictive, non-invasive device, intended to be placed on the participant's maternal abdomen during the intrapartum period, which can alert healthcare professionals of an impending cumulative blood loss of ≥500 ml (abnormal postpartum uterine bleeding) or cumulative bloo…
Sponsor: Baymatob Operations Pty Ltd • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New drug shows promise in slowing spread of aggressive prostate cancer
Disease control Recruiting nowThe purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk lo…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug may reduce insulin shots for young diabetes patients
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both admini…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
Could a simple heart procedure free millions from daily blood thinners?
Disease control Recruiting nowThe DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF). Current guidelines recommend continued anticoagulation based on stroke risk scores, even post-ablation, potentially exposing patie…
Early phase 1 • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Gene therapy aims to fix immune system in rare disease
Disease control OngoingThe goal of this clinical trial is to evaluate the safety and potential efficacy of the EN-374 treatment regimen and identify a dose level for further evaluation in participants with x-linked chronic granulomatous disease. The main questions it aims to answer are: * safety of t…
Phase 1/2 • Sponsor: Ensoma • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant lung cancer?
Disease control Recruiting nowThis study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.
Phase 3 • Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Light-Based blood test may spot lung cancer early
Diagnosis Recruiting nowThis prospective, multicenter observational study aims to evaluate the diagnostic and clinical monitoring performance of a nitride-based Raman biochip in participants with and without lung cancer. Peripheral blood samples will be collected and analyzed using the Raman biochip to …
Sponsor: Taichung Veterans General Hospital • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
New CAR-T therapy targets tough childhood cancers
Disease control Recruiting nowThis is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and \<18 years, ≥6 kg body weight \[BW\]) with mature B-cell neoplasms and aggressive lymphomas that rel…
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for Platinum-Resistant ovarian cancer: BL-B01D1 enters phase 3 trial
Disease control Recruiting nowThis trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
A smarter way to choose liver cancer treatment? a new model aims to match therapy to the patient.
Disease control CompletedUnresectable hepatocellular carcinoma (uHCC) constitutes a significant health burden in the Asia-Pacific (APAC) region, particularly in China, where it is frequently associated with hepatitis B virus (HBV) infection and diagnosed at advanced stages. Transarterial chemoembolizati…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo CAR-T therapy targets multiple cancer proteins
Disease control Stopped earlyThe study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell …
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Clot-Removal procedure turn the tide in severe stroke?
Disease control Recruiting nowA multicenter, prospective, open-label, blinded endpoint, randomized controlled trial designed to evaluate the efficacy and safety of best medical management (BMM) combined with endovascular treatment (EVT) versus BMM alone in acute basilar artery occlusion (BAO) patients with la…
Sponsor: The First Affiliated Hospital of Hainan Medical University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for stroke patients: drug may restore function after medium vessel blockages
Disease control Recruiting nowResults from recent several trials provided data showing limits to the effectiveness of thrombectomy for ischemic stroke due to medium vessel occlusions.The benefit-risk profile of thrombolysis for these patients has never been investigated. We initiated a multicenter, prospectiv…
Phase 3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells take aim at multiple myeloma from the start
Disease control Recruiting nowThis is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed multiple myeloma. Patients will receive lymphodepletion followed by a single infusion of RN12…
Phase 1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
Disease control Recruiting nowThis phase I/II trial tests the safety and effectiveness of receiving external beam radiation therapy (EBRT) and brachytherapy along with chemotherapy, consisting of cisplatin and paclitaxel, and immunotherapy, consisting of bevacizumab and pembrolizumab, for the treatment of pat…
Phase 1/2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new drug boost the power of existing liver cancer therapy?
Disease control Recruiting nowThis is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC.
Phase 1/2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
One-Time gene shot could free teens from bleeding disorder
Disease control Recruiting nowThis is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New immunotherapy cocktail aims to outsmart kidney cancer
Disease control OngoingThis is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC). The Phase III part of the study…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC